Anadys Pharmaceuticals Selects a Novel Oral Toll-Like Receptor Ligand as Drug Development Candidate for Cancer (Chronic Hepatitis C)

Anadys Pharmaceuticals Selects a Novel Oral Toll-Like Receptor Ligand as Drug Development Candidate for Cancer
FinanzNachrichten - Dec 13 1:17 PM
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals ( Nachrichten ), Inc. announced today that it has selected ANA773, a novel Toll-Like Receptor-7 (TLR-7) oral prodrug, for its next clinical development program.Save to My Web

Medivir: Candidate Drug Designated within the Tibotec Collaboration
[Press Release] Business Wire via Yahoo! Finance - Dec 28 11:59 PM
STOCKHOLM, Sweden----Dec. 29, 2005--The Hepatitis C Virus collaboration with Tibotec Pharmaceuticals Ltd has recently designated a Candidate Drug . The aim of the research collaboration is to identify and develop orally active inhibitors of the HCV protease NS3/4A.Save to My Web

Cyclosporine Shows Advantage Over Tacrolimus
RedNova - Jan 06 7:50 PM
The immunosuppressive agent cyclosporine has shown better efficacy than the leading anti-rejection drug tacrolimus when taken as an adjunctive therapy by liver transplant patients with hepatitis C.Save to My Web